$KROS News

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy

Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering Partners

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Keros Therapeutics Reveals $5M Share Repurchase Authorization

Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?

Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics CFO Keith Regnante Resigns, Effective Aug. 3; VP Finance Annita Tanini Named Interim Principal Financial Officer

Keros Therapeutics Appoints Anne Prener to its Board of Directors

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026